{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:45:12Z","timestamp":1792273512412,"version":"4.4.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12072-026-11097-1","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:05:50Z","timestamp":1779447950000},"page":"1299-1317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child\u2013Turcotte\u2013Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9950-1312","authenticated-orcid":false,"given":"Dhiraj","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Jothimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Bhoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru N.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Saigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"20","key":"11097_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"issue":"4","key":"11097_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030","journal-title":"J Hepatol"},{"issue":"1","key":"11097_CR3","doi-asserted-by":"publisher","DOI":"10.2217\/hep-2023-0002","volume":"10","author":"A Aly","year":"2023","unstructured":"Aly A, Fulcher N, Seal B, et al. Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting. Hepat Oncol. 2023;10(1): HEP47. https:\/\/doi.org\/10.2217\/hep-2023-0002","journal-title":"Hepat Oncol"},{"issue":"3","key":"11097_CR4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/hep4.1652","volume":"5","author":"R Cabrera","year":"2020","unstructured":"Cabrera R, Singal AG, Colombo M, et al. A real\u2010world observational cohort of patients with hepatocellular carcinoma: design and rationale for TARGET\u2010HCC. Hepatol Commun. 2020;5(3):538\u2013547. https:\/\/doi.org\/10.1002\/hep4.1652","journal-title":"Hepatol Commun"},{"issue":"5","key":"11097_CR5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","volume":"164","author":"MR Toh","year":"2023","unstructured":"Toh MR, Wong EYT, Wong SH, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164(5):766\u2013782. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.033","journal-title":"Gastroenterology"},{"issue":"3","key":"11097_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","volume":"68","author":"G D\u2019Amico","year":"2018","unstructured":"D\u2019Amico G, Morabito A, D\u2019Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68(3):563\u2013576. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.020","journal-title":"J Hepatol"},{"issue":"1","key":"11097_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2021.06.018","volume":"76","author":"G D\u2019Amico","year":"2022","unstructured":"D\u2019Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. J Hepatol. 2022;76(1):202\u2013207. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.018","journal-title":"J Hepatol"},{"issue":"4","key":"11097_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u2013974. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022","journal-title":"J Hepatol"},{"issue":"1","key":"11097_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-024-10773-4","volume":"19","author":"A Choudhury","year":"2025","unstructured":"Choudhury A, Kulkarni AV, Arora V, et al. Acute-on-chronic liver failure (ACLF): the \u2019Kyoto Consensus\u2019-steps from Asia. Hepatol Int. 2025;19(1):1\u201369. https:\/\/doi.org\/10.1007\/s12072-024-10773-4","journal-title":"Hepatol Int"},{"issue":"4","key":"11097_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","volume":"13","author":"SK Sarin","year":"2019","unstructured":"Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353\u2013390. https:\/\/doi.org\/10.1007\/s12072-019-09946-3","journal-title":"Hepatol Int"},{"issue":"3","key":"11097_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15861","volume":"45","author":"MS Schulz","year":"2025","unstructured":"Schulz MS, Angeli P, Trebicka J. Acute and non-acute decompensation of liver cirrhosis (47\/130). Liver Int. 2025;45(3): e15861. https:\/\/doi.org\/10.1111\/liv.15861","journal-title":"Liver Int"},{"issue":"3","key":"11097_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"issue":"9","key":"11097_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","volume":"10","author":"CAM Fulgenzi","year":"2024","unstructured":"Fulgenzi CAM, Scheiner B, D\u2019Alessio A, et al. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024;10(9):1253\u20131258. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2166","journal-title":"JAMA Oncol"},{"issue":"3","key":"11097_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","volume":"75","author":"M Kudo","year":"2021","unstructured":"Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75(3):600\u2013609. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.047","journal-title":"J Hepatol"},{"issue":"4","key":"11097_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","volume":"74","author":"L Rimassa","year":"2021","unstructured":"Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol. 2021;74(4):931\u2013943. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.026","journal-title":"J Hepatol"},{"issue":"6","key":"11097_CR16","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","volume":"65","author":"JA Marrero","year":"2016","unstructured":"Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol. 2016;65(6):1140\u20131147. https:\/\/doi.org\/10.1016\/j.jhep.2016.07.020","journal-title":"J Hepatol"},{"key":"11097_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","volume":"105","author":"MG McNamara","year":"2018","unstructured":"McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer. 2018;105:1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.031","journal-title":"Eur J Cancer"},{"issue":"4","key":"11097_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/hep.32468","volume":"76","author":"A D\u2019Alessio","year":"2022","unstructured":"D\u2019Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study. Hepatol Baltim Md. 2022;76(4):1000\u20131012. https:\/\/doi.org\/10.1002\/hep.32468","journal-title":"Hepatol Baltim Md"},{"key":"11097_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221148541","volume":"15","author":"J Cheon","year":"2023","unstructured":"Cheon J, Kim H, Kim HS, et al. Atezolizumab plus bevacizumab in patients with Child-Pugh B advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2023;15: 17588359221148541. https:\/\/doi.org\/10.1177\/17588359221148541","journal-title":"Ther Adv Med Oncol"},{"issue":"4_suppl","key":"11097_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2025.43.4_suppl.587","volume":"43","author":"M Ikeda","year":"2025","unstructured":"Ikeda M, Terashima T, Yamashita T, et al. A multicentre, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh class B cirrhosis: CHALLENGE trial final results. J Clin Oncol. 2025;43(4_suppl):587\u2013587. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.587","journal-title":"J Clin Oncol"},{"key":"11097_CR21","doi-asserted-by":"publisher","unstructured":"KIRROS: A phase II trial in progress of first-line atezolizumab (atezo) with or without bevacizumab (bev) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis. | Journal of Clinical Oncology. Accessed March 9, 2026. https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.TPS647","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS647"},{"issue":"8","key":"11097_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8): EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070","journal-title":"NEJM Evid"},{"issue":"4","key":"11097_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","volume":"83","author":"L Rimassa","year":"2025","unstructured":"Rimassa L, Chan SL, Sangro B, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025;83(4):899\u2013908. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.033","journal-title":"J Hepatol"},{"key":"11097_CR24","doi-asserted-by":"publisher","DOI":"10.1159\/000549955","author":"SL Chan","year":"2025","unstructured":"Chan SL, Kudo M, Sangro B, et al. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000549955","journal-title":"Liver Cancer"},{"issue":"10","key":"11097_CR25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","volume":"9","author":"E Xie","year":"2023","unstructured":"Xie E, Yeo YH, Scheiner B, et al. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncol. 2023;9(10):1423\u20131431. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3284","journal-title":"JAMA Oncol"},{"issue":"4","key":"11097_CR26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/HEP.0000000000000030","volume":"77","author":"I El Hajra","year":"2023","unstructured":"El Hajra I, Sanduzzi-Zamparelli M, Sapena V, et al. Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis. Hepatology. 2023;77(4):1139\u20131149. https:\/\/doi.org\/10.1097\/HEP.0000000000000030","journal-title":"Hepatology"},{"key":"11097_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-15126-4","volume":"25","author":"D Liu","year":"2025","unstructured":"Liu D, Yang Z, Wang L, et al. Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study. BMC Cancer. 2025;25: 1651. https:\/\/doi.org\/10.1186\/s12885-025-15126-4","journal-title":"BMC Cancer"},{"issue":"3","key":"11097_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000534303","volume":"13","author":"SY Hwang","year":"2023","unstructured":"Hwang SY, Lee SL, Liu H, Lee SS. Second-line treatment after failure of immune checkpoint inhibitors in hepatocellular carcinoma: tyrosine kinase inhibitor, retrial of immunotherapy, or locoregional therapy? Liver Cancer. 2023;13(3):246\u2013255. https:\/\/doi.org\/10.1159\/000534303","journal-title":"Liver Cancer"},{"issue":"3","key":"11097_CR29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v32.i3.111528","volume":"32","author":"S Ascari","year":"2026","unstructured":"Ascari S, Chen R, De Sinno A, et al. Post-immunotherapy second-line strategies for hepatocellular carcinoma: state of the art and ongoing trials. World J Gastroenterol. 2026;32(3): 111528. https:\/\/doi.org\/10.3748\/wjg.v32.i3.111528","journal-title":"World J Gastroenterol"},{"issue":"6","key":"11097_CR30","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1159\/000539897","volume":"13","author":"RS Finn","year":"2024","unstructured":"Finn RS, Galle PR, Ducreux M, et al. Efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150. Liver Cancer. 2024;13(6):655\u2013668. https:\/\/doi.org\/10.1159\/000539897","journal-title":"Liver Cancer"},{"issue":"10492","key":"11097_CR31","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405(10492):1851\u20131864. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9","journal-title":"Lancet"},{"issue":"1","key":"11097_CR32","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-2025-658","volume":"15","author":"T Kanda","year":"2026","unstructured":"Kanda T, Sasaki-Tanaka R, Kamimura H, Hayashi K, Kamimura K, Terai S. STRIDE sustained an overall survival benefit with safety profiles in unresectable hepatocellular carcinoma at 5-year follow-up. Hepatobiliary Surg Nutr. 2026;15(1): 17. https:\/\/doi.org\/10.21037\/hbsn-2025-658","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"11097_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/hepr.70033","volume":"56","author":"T Hatanaka","year":"2026","unstructured":"Hatanaka T, Yata Y, Hiraoka A, et al. Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis. Hepatol Res Off J Jpn Soc Hepatol. 2026;56(1):89\u201399. https:\/\/doi.org\/10.1111\/hepr.70033","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"issue":"8","key":"11097_CR34","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/liv.14977","volume":"41","author":"M Allaire","year":"2021","unstructured":"Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses\u2026. Liver Int. 2021;41(8):1734\u20131743. https:\/\/doi.org\/10.1111\/liv.14977","journal-title":"Liver Int"},{"issue":"1","key":"11097_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hep.27864","volume":"62","author":"F Faitot","year":"2015","unstructured":"Faitot F, Allard MA, Pittau G, et al. Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. Hepatology. 2015;62(1):179\u2013187. https:\/\/doi.org\/10.1002\/hep.27864","journal-title":"Hepatology"},{"issue":"2","key":"11097_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12328-022-01605-9","volume":"15","author":"A Furusawa","year":"2022","unstructured":"Furusawa A, Naganuma A, Suzuki Y, et al. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Clin J Gastroenterol. 2022;15(2):451\u2013459. https:\/\/doi.org\/10.1007\/s12328-022-01605-9","journal-title":"Clin J Gastroenterol"},{"issue":"8","key":"11097_CR37","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1634\/theoncologist.2011-0465","volume":"17","author":"V Boige","year":"2012","unstructured":"Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17(8):1063\u20131072. https:\/\/doi.org\/10.1634\/theoncologist.2011-0465","journal-title":"Oncologist"},{"issue":"2","key":"11097_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101785","volume":"46","author":"B Campion","year":"2022","unstructured":"Campion B, Larrey E, Wagner M, Rudler M, Thabut D, Allaire M. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A \u201cmenage \u00e0 trois\u201d\u202f! Clin Res Hepatol Gastroenterol. 2022;46(2): 101785. https:\/\/doi.org\/10.1016\/j.clinre.2021.101785","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"11097_CR39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jhep.2022.11.019","volume":"78","author":"D Thabut","year":"2023","unstructured":"Thabut D, Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. J Hepatol. 2023;78(3):658\u2013662. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.019","journal-title":"J Hepatol"},{"issue":"1","key":"11097_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.gastro.2020.09.026","volume":"160","author":"O Nicoar\u0103-Farc\u0103u","year":"2021","unstructured":"Nicoar\u0103-Farc\u0103u O, Han G, Rudler M, et al. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology. 2021;160(1):193-205.e10. https:\/\/doi.org\/10.1053\/j.gastro.2020.09.026","journal-title":"Gastroenterology"},{"issue":"7","key":"11097_CR41","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/apt.14485","volume":"47","author":"N Pfisterer","year":"2018","unstructured":"Pfisterer N, Dexheimer C, Fuchs EM, et al. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther. 2018;47(7):966\u2013979. https:\/\/doi.org\/10.1111\/apt.14485","journal-title":"Aliment Pharmacol Ther"},{"issue":"50","key":"11097_CR42","doi-asserted-by":"publisher","first-page":"82473","DOI":"10.18632\/oncotarget.12666","volume":"7","author":"H Zhang","year":"2016","unstructured":"Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016;7(50):82473\u201382481. https:\/\/doi.org\/10.18632\/oncotarget.12666","journal-title":"Oncotarget"},{"issue":"1","key":"11097_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/HEP.0000000000000291","volume":"79","author":"M Allaire","year":"2024","unstructured":"Allaire M, Thabut D. Portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management. Hepatol Baltim Md. 2024;79(1):213\u2013223. https:\/\/doi.org\/10.1097\/HEP.0000000000000291","journal-title":"Hepatol Baltim Md"},{"issue":"2","key":"11097_CR44","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024","journal-title":"J Hepatol"},{"issue":"12","key":"11097_CR45","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","volume":"39","author":"SC Bischoff","year":"2020","unstructured":"Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr. 2020;39(12):3533\u20133562. https:\/\/doi.org\/10.1016\/j.clnu.2020.09.001","journal-title":"Clin Nutr"},{"issue":"2","key":"11097_CR46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","volume":"75","author":"M Senzolo","year":"2021","unstructured":"Senzolo M, Garcia-Tsao G, Garc\u00eda-Pag\u00e1n JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol. 2021;75(2):442\u2013453. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.029","journal-title":"J Hepatol"},{"issue":"1","key":"11097_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40644-022-00451-9","volume":"22","author":"H Yan","year":"2022","unstructured":"Yan H, Qiu Z, Xiang Z, Feng K, Huang M, Gao F. TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience. Cancer Imaging. 2022;22(1):13. https:\/\/doi.org\/10.1186\/s40644-022-00451-9","journal-title":"Cancer Imaging"},{"issue":"6","key":"11097_CR48","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s12664-024-01646-7","volume":"43","author":"S Giri","year":"2024","unstructured":"Giri S, Singh A, Das S, et al. Efficacy and safety of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma-A systematic review and meta-analysis. Indian J Gastroenterol. 2024;43(6):1121\u20131135. https:\/\/doi.org\/10.1007\/s12664-024-01646-7","journal-title":"Indian J Gastroenterol"},{"issue":"12","key":"11097_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101233","volume":"6","author":"S Piano","year":"2024","unstructured":"Piano S, Reiberger T, Bosch J. Mechanisms and implications of recompensation in cirrhosis. JHEP Rep. 2024;6(12): 101233. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101233","journal-title":"JHEP Rep"},{"issue":"10","key":"11097_CR50","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/liv.15676","volume":"43","author":"BS Hofer","year":"2023","unstructured":"Hofer BS, Simbrunner B, Hartl L, et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver Int. 2023;43(10):2220\u20132231. https:\/\/doi.org\/10.1111\/liv.15676\\","journal-title":"Liver Int"},{"issue":"6","key":"11097_CR51","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","volume":"77","author":"Q Wang","year":"2022","unstructured":"Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for recompensation in Entecavir-treated patients with Hepatitis B-related decompensated cirrhosis. J Hepatol. 2022;77(6):1564\u20131572. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.037","journal-title":"J Hepatol"},{"issue":"10","key":"11097_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70362","volume":"45","author":"L Stella","year":"2025","unstructured":"Stella L, Cabibbo G, Celsa C, et al. Hepatitis C eradication improves oncologic and clinical outcomes in patients treated with Atezolizumab plus Bevacizumab. Liver Int. 2025;45(10): e70362. https:\/\/doi.org\/10.1111\/liv.70362","journal-title":"Liver Int"},{"issue":"9","key":"11097_CR53","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.14309\/ajg.0000000000003259","volume":"120","author":"AK Singal","year":"2024","unstructured":"Singal AK, Panneerselvam D, Arab JP, Im G, Kuo YF. Delisting from liver transplant list for improvement and recompensation among decompensated patients at one year. Am J Gastroenterol. 2024;120(9):2086\u20132092. https:\/\/doi.org\/10.14309\/ajg.0000000000003259","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"11097_CR54","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","volume":"167","author":"M Premkumar","year":"2024","unstructured":"Premkumar M, Dhiman RK, Duseja A, et al. Recompensation of chronic Hepatitis C-related decompensated cirrhosis following Direct-Acting Antiviral therapy: prospective cohort study from a Hepatitis C Virus Elimination Program. Gastroenterology. 2024;167(7):1429\u20131445. https:\/\/doi.org\/10.1053\/j.gastro.2024.08.018","journal-title":"Gastroenterology"},{"issue":"4","key":"11097_CR55","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/hep.28992","volume":"65","author":"A Berzigotti","year":"2017","unstructured":"Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology. 2017;65(4):1293\u20131305. https:\/\/doi.org\/10.1002\/hep.28992","journal-title":"Hepatology"},{"issue":"4","key":"11097_CR56","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000529636","volume":"12","author":"P Merle","year":"2023","unstructured":"Merle P, Kudo M, Edeline J, et al. Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the phase 3 KEYNOTE-240 trial. Liver Cancer. 2023;12(4):309\u2013320. https:\/\/doi.org\/10.1159\/000529636","journal-title":"Liver Cancer"},{"issue":"1","key":"11097_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00604-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"11097_CR58","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","volume":"161","author":"PK Haber","year":"2021","unstructured":"Haber PK, Puigveh\u00ed M, Castet F, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). Gastroenterology. 2021;161(3):879\u2013898. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.008","journal-title":"Gastroenterology"},{"issue":"2","key":"11097_CR59","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","volume":"79","author":"T Meyer","year":"2023","unstructured":"Meyer T, Galani S, Lopes A, Vogel A. Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease. J Hepatol. 2023;79(2):e73\u2013e76. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.012","journal-title":"J Hepatol"},{"key":"11097_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1598193","volume":"15","author":"S Xu","year":"2025","unstructured":"Xu S, Pang Q, Wei M, et al. Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors. Front Cell Infect Microbiol. 2025;15: 1598193. https:\/\/doi.org\/10.3389\/fcimb.2025.1598193","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"11097_CR61","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502\u2013583","journal-title":"J Hepatol"},{"issue":"3","key":"11097_CR62","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","volume":"80","author":"C Celsa","year":"2024","unstructured":"Celsa C, Cabibbo G, Fulgenzi CAM, et al. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. J Hepatol. 2024;80(3):431\u2013442. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.040","journal-title":"J Hepatol"},{"issue":"2","key":"11097_CR63","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","volume":"72","author":"B Sangro","year":"2020","unstructured":"Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72(2):320\u2013341. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.021","journal-title":"J Hepatol"},{"issue":"1","key":"11097_CR64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72(1):315\u2013329. https:\/\/doi.org\/10.1002\/hep.31227","journal-title":"Hepatology"},{"issue":"7","key":"11097_CR65","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/gutjnl-2024-332125","volume":"74","author":"E De Martin","year":"2025","unstructured":"De Martin E, Fulgenzi CAM, Celsa C, et al. Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events. Gut. 2025;74(7):1165\u20131177. https:\/\/doi.org\/10.1136\/gutjnl-2024-332125","journal-title":"Gut"},{"issue":"17","key":"11097_CR66","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"5","key":"11097_CR67","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s12072-025-10825-3","volume":"19","author":"K Matsumoto","year":"2025","unstructured":"Matsumoto K, Kanda T, Wakatsuki J, et al. Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors. Hepatol Int. 2025;19(5):1221\u20131230. https:\/\/doi.org\/10.1007\/s12072-025-10825-3","journal-title":"Hepatol Int"},{"issue":"3","key":"11097_CR68","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2668","volume":"8","author":"SM Durbin","year":"2025","unstructured":"Durbin SM, Zubiri L, Perlman K, et al. Late-onset immune-related adverse events after immune checkpoint inhibitor therapy. JAMA Netw Open. 2025;8(3): e252668. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.2668","journal-title":"JAMA Netw Open"},{"key":"11097_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320","volume":"12","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Zhang J, Xu L, et al. Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis. Front Immunol. 2021;12: 730320. https:\/\/doi.org\/10.3389\/fimmu.2021.730320","journal-title":"Front Immunol"},{"issue":"9","key":"11097_CR70","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 2019;5(9):1310\u20131317. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"issue":"4","key":"11097_CR71","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2468-1253(24)00247-4","volume":"10","author":"BY Zhong","year":"2025","unstructured":"Zhong BY, Fan W, Guan JJ, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2025;10(4):369\u2013386. https:\/\/doi.org\/10.1016\/S2468-1253(24)00247-4","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"11097_CR72","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u20131965. https:\/\/doi.org\/10.1097\/HEP.0000000000000466","journal-title":"Hepatology"},{"issue":"10474","key":"11097_CR73","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Lond Engl. 2025;405(10474):216\u2013232. https:\/\/doi.org\/10.1016\/S0140-6736(24)02551-0","journal-title":"Lancet Lond Engl"},{"issue":"10474","key":"11097_CR74","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405(10474):203\u2013215. https:\/\/doi.org\/10.1016\/S0140-6736(24)02575-3","journal-title":"Lancet"},{"issue":"4","key":"11097_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101110","volume":"28","author":"F Pi\u00f1ero","year":"2023","unstructured":"Pi\u00f1ero F, Anders M, Bermudez C, et al. Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC. Ann Hepatol. 2023;28(4): 101110. https:\/\/doi.org\/10.1016\/j.aohep.2023.101110","journal-title":"Ann Hepatol"},{"issue":"6","key":"11097_CR76","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/2050640619840199","volume":"7","author":"B Scheiner","year":"2019","unstructured":"Scheiner B, Ulbrich G, Mandorfer M, et al. Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United Eur Gastroenterol J. 2019;7(6):850\u2013858. https:\/\/doi.org\/10.1177\/2050640619840199","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"11097_CR77","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","volume":"82","author":"P Tabrizian","year":"2025","unstructured":"Tabrizian P, Holzner ML, Ajmera V, et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study. J Hepatol. 2025;82(3):512\u2013522. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.003","journal-title":"J Hepatol"},{"issue":"3","key":"11097_CR78","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/ajt.15617","volume":"20","author":"MF Nordness","year":"2020","unstructured":"Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant. 2020;20(3):879\u2013883. https:\/\/doi.org\/10.1111\/ajt.15617","journal-title":"Am J Transplant"},{"key":"11097_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2021.101386","volume":"66","author":"GH Chen","year":"2021","unstructured":"Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period. Transpl Immunol. 2021;66: 101386. https:\/\/doi.org\/10.1016\/j.trim.2021.101386","journal-title":"Transpl Immunol"},{"issue":"5","key":"11097_CR80","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/ajt.16448","volume":"21","author":"P Tabrizian","year":"2021","unstructured":"Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant. 2021;21(5):1979\u20131980. https:\/\/doi.org\/10.1111\/ajt.16448","journal-title":"Am J Transplant"},{"issue":"4","key":"11097_CR81","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1159\/000529023","volume":"41","author":"A Schmiderer","year":"2023","unstructured":"Schmiderer A, Zoller H, Niederreiter M, et al. Liver transplantation after successful downstaging of a locally advanced hepatocellular carcinoma with systemic therapy. Dig Dis. 2023;41(4):641\u2013644. https:\/\/doi.org\/10.1159\/000529023","journal-title":"Dig Dis"},{"issue":"12","key":"11097_CR82","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1038\/ajg.2017.387","volume":"112","author":"A Varkaris","year":"2017","unstructured":"Varkaris A, Lewis DW, Nugent FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma. Am J Gastroenterol. 2017;112(12):1895\u20131896. https:\/\/doi.org\/10.1038\/ajg.2017.387","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"11097_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03226-3","volume":"16","author":"MS Rezaee-Zavareh","year":"2025","unstructured":"Rezaee-Zavareh MS, Hwang SY, Kim N, Adetyan H, Tran NH, Yang JD. Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors. Discov Oncol. 2025;16(1): 1431. https:\/\/doi.org\/10.1007\/s12672-025-03226-3","journal-title":"Discov Oncol"},{"issue":"5","key":"11097_CR84","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","volume":"82","author":"B Moeckli","year":"2025","unstructured":"Moeckli B, Wassmer CH, El Hajji S, et al. Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study. Hepatology. 2025;82(5):1122\u20131137. https:\/\/doi.org\/10.1097\/HEP.0000000000001289","journal-title":"Hepatology"},{"key":"11097_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2026.02.019","author":"S Bhoori","year":"2026","unstructured":"Bhoori S, Rivoltini L, Pinato DJ, et al. Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL). J Hepatol. 2026. https:\/\/doi.org\/10.1016\/j.jhep.2026.02.019","journal-title":"J Hepatol"},{"issue":"5","key":"11097_CR86","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","volume":"161","author":"N Mehta","year":"2021","unstructured":"Mehta N, Frenette C, Tabrizian P, et al. Downstaging outcomes for hepatocellular carcinoma: results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021;161(5):1502\u20131512. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.033","journal-title":"Gastroenterology"},{"key":"11097_CR87","unstructured":"RenJi Hospital. Safety and Efficacy Study of Pembrolizumab in Combination With LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant as Neoadjuvant TherapY--PLENTY Randomized Clinical Trial. clinicaltrials.gov; 2020. Accessed March 9, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04425226"},{"issue":"4","key":"11097_CR88","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2024.05.037","volume":"81","author":"M Li","year":"2024","unstructured":"Li M, Bhoori S, Mehta N, Mazzaferro V. Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation. J Hepatol. 2024;81(4):743\u2013755. https:\/\/doi.org\/10.1016\/j.jhep.2024.05.037","journal-title":"J Hepatol"},{"issue":"21","key":"11097_CR89","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1002\/cncr.33134","volume":"126","author":"I Owoyemi","year":"2020","unstructured":"Owoyemi I, Vaughan LE, Costello CM, et al. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis. Cancer. 2020;126(21):4780\u20134787. https:\/\/doi.org\/10.1002\/cncr.33134","journal-title":"Cancer"},{"issue":"10","key":"11097_CR90","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11150","volume":"12","author":"O Al Jarroudi","year":"2020","unstructured":"Al Jarroudi O, Ulusakarya A, Almohamad W, Afqir S, Morere JF. Anti-Programmed Cell Death Protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: A report of three cases. Cureus. 2020;12(10): e11150. https:\/\/doi.org\/10.7759\/cureus.11150","journal-title":"Cureus"},{"issue":"3","key":"11097_CR91","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/hep.29575","volume":"67","author":"A Rammohan","year":"2018","unstructured":"Rammohan A, Reddy MS, Farouk M, Vargese J, Rela M. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet? Hepatology. 2018;67(3):1166\u20131168. https:\/\/doi.org\/10.1002\/hep.29575","journal-title":"Hepatology"},{"issue":"5","key":"11097_CR92","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2217\/imt-2020-0014","volume":"12","author":"A Pandey","year":"2020","unstructured":"Pandey A, Cohen DJ. Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection. Immunotherapy. 2020;12(5):287\u2013292. https:\/\/doi.org\/10.2217\/imt-2020-0014","journal-title":"Immunotherapy"},{"issue":"2","key":"11097_CR93","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/LVT.0000000000000550","volume":"32","author":"D Kahramangil","year":"2026","unstructured":"Kahramangil D, Zarrinpar A, Sahin I. Immune checkpoint inhibitors in the posttransplant landscape of HCC: A systematic literature review. Liver Transpl. 2026;32(2):283\u2013295. https:\/\/doi.org\/10.1097\/LVT.0000000000000550","journal-title":"Liver Transpl"},{"issue":"3","key":"11097_CR94","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","volume":"81","author":"C Celsa","year":"2025","unstructured":"Celsa C, Cabibbo G, Fulgenzi CAM, et al. Hepatic decompensation is the major driver of mortality in patients with HCC treated with Atezolizumab plus Bevacizumab: the impact of successful antiviral treatment. Hepatology. 2025;81(3):837\u2013852. https:\/\/doi.org\/10.1097\/HEP.0000000000001026","journal-title":"Hepatology"},{"key":"11097_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.07.020","author":"G Cabibbo","year":"2025","unstructured":"Cabibbo G, Celsa C, Bhoori S, Reiberger T, Pinato DJ, Camm\u00e0 C. Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.07.020","journal-title":"J Hepatol"},{"issue":"4","key":"11097_CR96","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000529173","volume":"12","author":"A Vogel","year":"2023","unstructured":"Vogel A, Kelley RK, Johnson P, et al. Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: A systematic literature review. Liver Cancer. 2023;12(4):372\u2013391. https:\/\/doi.org\/10.1159\/000529173","journal-title":"Liver Cancer"},{"issue":"6","key":"11097_CR97","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550\u2013558. https:\/\/doi.org\/10.1200\/JCO.2014.57.9151","journal-title":"J Clin Oncol"},{"issue":"5","key":"11097_CR98","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000529996","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Cheng AL, et al. Albumin-Bilirubin Grade analyses of Atezolizumab plus Bevacizumab versus Sorafenib in patients with unresectable hepatocellular carcinoma: A post hoc analysis of the Phase III IMbrave150 study. Liver Cancer. 2023;12(5):479\u2013493. https:\/\/doi.org\/10.1159\/000529996","journal-title":"Liver Cancer"},{"issue":"5","key":"11097_CR99","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1159\/000516490","volume":"10","author":"A Vogel","year":"2021","unstructured":"Vogel A, Frenette C, Sung M, et al. Baseline liver function and subsequent outcomes in the Phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma. Liver Cancer. 2021;10(5):510\u2013521. https:\/\/doi.org\/10.1159\/000516490","journal-title":"Liver Cancer"},{"issue":"1","key":"11097_CR100","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jhep.2022.10.018","volume":"78","author":"G Cabibbo","year":"2023","unstructured":"Cabibbo G, Bruix J. Radiological endpoints as surrogates for survival benefit in hepatocellular carcinoma trials: all that glitters is not gold. J Hepatol. 2023;78(1):8\u201311. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.018","journal-title":"J Hepatol"},{"issue":"5","key":"11097_CR101","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamaoncol.2021.8206","volume":"8","author":"IF Tannock","year":"2022","unstructured":"Tannock IF, Pond GR, Booth CM. Biased evaluation in cancer drug trials-how use of progression-free survival as the primary end point can mislead. JAMA Oncol. 2022;8(5):679\u2013680. https:\/\/doi.org\/10.1001\/jamaoncol.2021.8206","journal-title":"JAMA Oncol"},{"issue":"6","key":"11097_CR102","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s12072-025-10875-7","volume":"19","author":"M Ohara","year":"2025","unstructured":"Ohara M, Suda G, Kohya R, et al. Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatol Int. 2025;19(6):1371\u20131381. https:\/\/doi.org\/10.1007\/s12072-025-10875-7","journal-title":"Hepatol Int"},{"key":"11097_CR103","doi-asserted-by":"publisher","DOI":"10.1159\/000547792","author":"A Vitale","year":"2025","unstructured":"Vitale A, Kim JS, Cabibbo G, et al. Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000547792","journal-title":"Liver Cancer"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11097-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11097-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11097-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:18:40Z","timestamp":1792271920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11097-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11097"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11097-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}